Extensive impairment of triazolam and alprazolam clearance by short-term low-dose ritonavir: the clinical dilemma of concurrent inhibition and induction

J Clin Psychopharmacol. 1999 Aug;19(4):293-6. doi: 10.1097/00004714-199908000-00001.
No abstract available

Publication types

  • Editorial
  • Research Support, U.S. Gov't, P.H.S.
  • Review

MeSH terms

  • Acquired Immunodeficiency Syndrome / drug therapy*
  • Acquired Immunodeficiency Syndrome / enzymology
  • Alprazolam / pharmacokinetics*
  • Animals
  • Aryl Hydrocarbon Hydroxylases*
  • Cytochrome P-450 CYP3A
  • Cytochrome P-450 Enzyme Inhibitors*
  • Cytochrome P-450 Enzyme System / blood
  • Drug Interactions
  • Enzyme Induction / drug effects
  • HIV Protease Inhibitors / administration & dosage
  • HIV Protease Inhibitors / adverse effects*
  • Humans
  • Hypnotics and Sedatives / pharmacokinetics*
  • Metabolic Clearance Rate / drug effects
  • Microsomes, Liver / drug effects
  • Microsomes, Liver / enzymology
  • Oxidoreductases, N-Demethylating / antagonists & inhibitors*
  • Oxidoreductases, N-Demethylating / blood
  • Ritonavir / administration & dosage
  • Ritonavir / adverse effects*
  • Triazolam / pharmacokinetics*

Substances

  • Cytochrome P-450 Enzyme Inhibitors
  • HIV Protease Inhibitors
  • Hypnotics and Sedatives
  • Triazolam
  • Cytochrome P-450 Enzyme System
  • Aryl Hydrocarbon Hydroxylases
  • Cytochrome P-450 CYP3A
  • Oxidoreductases, N-Demethylating
  • Ritonavir
  • Alprazolam